Trial Profile
An open label study to determine the safety, tolerability, excretion balance and pharmacokinetics of [14C] GW856553, administered as a single dose of an oral solution to healthy adult male subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Losmapimod (Primary)
- Indications Atherosclerosis; Chronic obstructive pulmonary disease; Depressive disorders; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors GSK
- 29 Feb 2008 New trial record.